Tabula Bio is a genomics and AI company advancing health-related research at the intersection of molecular biology, biomedical data, and artificial intelligence. Our mission is to build predictive models that support early detection, individualized risk assessment, and precision treatment strategies for complex human diseases.

Our current focus is on improving polygenic risk models for highly heritable conditions such as autism and schizophrenia, where traditional methods have struggled to deliver clinical utility. By combining multi-scale biological signals—including genomic, epigenomic, and transcriptomic data—with interpretable machine learning, we aim to make genetic risk scores more accurate, inclusive, and actionable.

We are committed to conducting ethically responsible, high-impact research that contributes to public health and advances the broader scientific understanding of disease. Our work is designed to be rigorous, transparent, and aligned with open-science principles, with a roadmap to publish and share derived findings with the research community.

Tabula Bio is headquartered in the United States and led by a multidisciplinary team of scientists, engineers, and clinical researchers. Our first research outputs are expected in 2025.

TABULA BIO

Get in touch